Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Andrea Rosi is active.

Publication


Featured researches published by Andrea Rosi.


Hiv Medicine | 2010

Changing patterns in HIV-1 non-B clade prevalence and diversity in Italy over three decades*

Alessia Lai; Chiara Riva; A Marconi; M Balestrieri; Francesca Razzolini; G Meini; Ilaria Vicenti; Andrea Rosi; Francesco Saladini; Ilaria Caramma; Marco Franzetti; V Rossini; Andrea Galli; Massimo Galli; Michela Violin; Maurizio Zazzi; Claudia Balotta

HIV‐1 non‐B subtypes have recently entered Western Europe following immigration from other regions. The distribution of non‐B clades and their association with demographic factors, over the entire course of the HIV‐1 epidemic, have not been fully investigated in Italy.


Clinical Microbiology and Infection | 2012

Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010

Manuela Colafigli; Carlo Torti; Enrico Maria Trecarichi; L. Albini; Andrea Rosi; Valeria Micheli; Nino Manca; G. Penco; Bianca Bruzzone; Grazia Punzi; Patrizia Corsi; Giustino Parruti; Patrizia Bagnarelli; Laura Monno; Angela Gonnelli; Roberto Cauda; S. Di Giambenedetto

Prevalence and predictors of transmitted drug resistance (TDR), defined as the presence of at least one WHO surveillance drug resistance mutation (SDRM), were investigated in antiretroviral-naïve HIV-1-infected patients, with a genotypic resistance test (GRT) performed ≤6 months before starting cART between 2000 and 2010. 3163 HIV-1 sequences were selected (69% subtype B). Overall, the prevalence of TDR was 12% (13.2% subtype B, 9% non-B). TDR significantly declined overall and for the single drug classes. Older age independently predicted increased odds of TDR, whereas a more recent GRT, a higher HIV-RNA and C vs. B subtype predicted lower odds of TDR.


BMC Infectious Diseases | 2013

Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort.

István Bartha; Matthias Assel; Peter M. A. Sloot; Maurizio Zazzi; Carlo Torti; Eugen Schülter; Andrea De Luca; Anders Sönnerborg; Ana B. Abecasis; Kristel Van Laethem; Andrea Rosi; Jenny Svärd; Roger Paredes; David A. M. C. van de Vijver; Anne-Mieke Vandamme; Viktor Müller

BackgroundSuperinfection with drug resistant HIV strains could potentially contribute to compromised therapy in patients initially infected with drug-sensitive virus and receiving antiretroviral therapy. To investigate the importance of this potential route to drug resistance, we developed a bioinformatics pipeline to detect superinfection from routinely collected genotyping data, and assessed whether superinfection contributed to increased drug resistance in a large European cohort of viremic, drug treated patients.MethodsWe used sequence data from routine genotypic tests spanning the protease and partial reverse transcriptase regions in the Virolab and EuResist databases that collated data from five European countries. Superinfection was indicated when sequences of a patient failed to cluster together in phylogenetic trees constructed with selected sets of control sequences. A subset of the indicated cases was validated by re-sequencing pol and env regions from the original samples.Results4425 patients had at least two sequences in the database, with a total of 13816 distinct sequence entries (of which 86% belonged to subtype B). We identified 107 patients with phylogenetic evidence for superinfection. In 14 of these cases, we analyzed newly amplified sequences from the original samples for validation purposes: only 2 cases were verified as superinfections in the repeated analyses, the other 12 cases turned out to involve sample or sequence misidentification. Resistance to drugs used at the time of strain replacement did not change in these two patients. A third case could not be validated by re-sequencing, but was supported as superinfection by an intermediate sequence with high degenerate base pair count within the time frame of strain switching. Drug resistance increased in this single patient.ConclusionsRoutine genotyping data are informative for the detection of HIV superinfection; however, most cases of non-monophyletic clustering in patient phylogenies arise from sample or sequence mix-up rather than from superinfection, which emphasizes the importance of validation. Non-transient superinfection was rare in our mainly treatment experienced cohort, and we found a single case of possible transmitted drug resistance by this route. We therefore conclude that in our large cohort, superinfection with drug resistant HIV did not compromise the efficiency of antiretroviral treatment.


Journal of Medical Virology | 2014

Local and global spatio-temporal dynamics of HIV-1 subtype F1.

Alessia Lai; Massimo Ciccozzi; Marco Franzetti; Francesco R. Simonetti; Giorgio Bozzi; Francesca Binda; Andrea Rosi; Stefano Bonora; Andrea De Luca; Claudia Balotta; Gianguglielmo Zehender

Previous studies have attempted to explore the origin of the F1 subtype, but the precise origin of the Romanian and South American F1 variants remains controversial. As the F1 subtype is the most frequent non‐B variant among Europeans residing in Italy, the aim of this study was to estimate its phylogeography in order to reconstruct its origin and route of dispersion. The phylogeographical analyses, which were made using the Bayesian Markov Chain Monte Carlo approach and BEAST software, revealed two significant clades: the first included all of the Romanian strains together with a few Italian and four African isolates; the second encompassed all of the South American sequences and the large majority of Italian variants. By putting the African reference sequences into two discrete groups based on specific countries, phylogeographic analysis indicated that the F1 epidemic originated in Cameroon/Democratic Republic of Congo in the early 1940s, and was exported to South America 10 years later. Subsequently, the F1 virus spread to Angola and, from there, was exported to Romania in the early 1960s. It reached Italy in the 1970s from South America and Romania. The South American and Romanian variants of F1 have different African countries of origin and different temporal spreads. The South American variant seems to be characterized by multiple introduction events, whereas the Romanian strain probably spread as a result of a single entry. Two different pathways from South America and Romania led the F1 variant to Italy in the 1970s. J. Med. Virol. 86:186–192, 2014.


AIDS Research and Human Retroviruses | 2012

Near Full-Length Sequence Analysis of HIV Type 1 BF Recombinants from Italy

Francesco Saladini; Brian T. Foley; Andrea Rosi; Ilaria Vicenti; Giulio Nannetti; Genny Meini; Francesca Razzolini; Maurizio Zazzi

Recombination between HIV-1 subtypes B and F has generated several circulating and unique recombinant forms, particularly in Latin American areas. In Italy, subtype B is highly prevalent while subtype F is the most common pure non-B subtype. To investigate the recombination pattern in Italian BF recombinant viruses, we characterized full-length sequences derived from 15 adult patients, mostly Italian and infected by the heterosexual route. One of the BF mosaics was a CRF29, three sequences clustered with low bootstrap values with CRF39, CRF40, and CRF42. With the exception of the CRF29-like sequence, the other recombination patterns were unique, but two possible clusters were identified. Analysis of the gp120 V3 domain suggested a possible link with subtype F from Eastern Europe rather than from Latin America, favoring the hypothesis of local recombination between clade B and F viruses over that of import of BF recombinants from Latin America. HIV-1 subtypes B and F appear prone to generation of unique recombinants in Italy, warranting epidemiological surveillance and investigation of a possible clinical significance.


Journal of Clinical Microbiology | 2010

Impact of remote versus local sampling on sensitivity of genotypic antiretroviral resistance testing.

Maddalena Balestrieri; Antonella Marconi; Genny Meini; Andrea Rosi; Francesco Saladini; Ilaria Vicenti; Francesca Razzolini; Maurizio Zazzi

Genotypic tests are commonly used in clinical practice to infer human immunodeficiency virus type 1 (HIV-1) susceptibility to licensed antiretroviral drugs ([3][1]). Viral RNA extracted from patient plasma by standardized methods is used as the source material for reverse transcription (RT)-PCR


Journal of Antimicrobial Chemotherapy | 2012

Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy

Ilaria Vicenti; Andrea Rosi; Francesco Saladini; Genny Meini; Francesco Pippi; Barbara Rossetti; Letizia Sidella; Simona Di Giambenedetto; Paolo Almi; Andrea De Luca; Cinzia Caudai; Maurizio Zazzi


AIDS Research and Human Retroviruses | 2015

Frequent Detection of Antiretroviral Drug Resistance in HIV-1-Infected Orphaned Children Followed at a Donor-Funded Rural Pediatric Clinic in Dodoma, Tanzania

Genny Meini; Maddalena Balestrieri; Sergio Cianchino; Danilo Tacconi; Marco Rossi de Gasperis; Carlo Concato; Ilaria Vicenti; Andrea Rosi; Francesco Saladini; Francesco Callea; Maurizio Zazzi


Journal of Virological Methods | 2015

Low-cost simultaneous detection of CCR5-delta32 and HLA-B*5701 alleles in human immunodeficiency virus type 1 infected patients by selective multiplex endpoint PCR

Andrea Rosi; Genny Meini; Angelo Materazzi; Ilaria Vicenti; Francesco Saladini; Maurizio Zazzi


BMC Infectious Diseases | 2013

Stability of unfrozen whole blood DNA for remote genotypic analysis of HIV-1 coreceptor tropism

Genny Meini; Angelo Materazzi; Francesco Saladini; Andrea Rosi; Ilaria Vicenti; Michele Mancini; Antonella Pirazzoli; Cinzia Caudai; Maurizio Zazzi

Collaboration


Dive into the Andrea Rosi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge